Linical Co. Ltd. | Income Statement

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Sales/Revenue
3,722
4,872
7,667
8,356
9,113
11,313
Cost of Goods Sold (COGS) incl. D&A
2,301
3,133
4,312
4,777
5,677
7,819
Gross Income
1,421
1,739
3,355
3,578
3,436
3,495
SG&A Expense
714
862
1,342
1,389
1,510
2,189
EBIT
706
877
2,012
2,129
1,847
1,213
Unusual Expense
-
106
11
67
10
99
Non Operating Income/Expense
1
31
12
50
6
62
Interest Expense
5
6
8
5
4
13
Pretax Income
704
735
1,986
2,011
1,826
1,164
Income Tax
255
298
655
563
530
596
Consolidated Net Income
449
437
1,331
1,448
1,296
568
Net Income
449
437
1,331
1,448
1,296
568
Net Income After Extraordinaries
449
437
1,331
1,448
1,296
568
Net Income Available to Common
449
437
1,331
1,448
1,296
568
EPS (Basic)
19.71
19.18
58.40
63.59
57.02
25.09
Basic Shares Outstanding
23
23
23
23
23
23
EPS (Diluted)
19.71
19.18
58.40
63.59
57.02
25.09
Diluted Shares Outstanding
23
23
23
23
23
23
EBITDA
722
965
2,203
2,332
2,057
1,664
Other Operating Expense
-
-
-
61
80
93
Non-Operating Interest Income
2
1
5
3
1
2

About Linical Co.

View Profile
Address
Shin-Osaka Brick Building, 10/F
Osaka Osaka 532
Japan
Employees -
Website http://www.linical.co.jp
Updated 07/08/2019
Linical Co., Ltd. engages in pharmaceutical contract research projects providing consulting, monitoring, and quality control services to pharmaceutical companies. It operates through the Contract Research Organization (CRO) Business and Contract Sales Organization (CSO) Business segments. The CRO Business segment provides outsourced pharmaceutical development services.